mdprostate helps radiologists and urologists come to informed conclusions and make the best treatment decisions when assessing prostate carcinoma.

The AI-based tool provides a fully-automated lesion classification according to PI-RADS 2.1 and is fully integrated with all PACS systems. In less than 3 minutes¹ , users receive a report including additional quantitative parameters such as prostate volume or changes in lesions compared to previous examinations. Additionally, all reports include an intuitive graphical representation of lesions on a sector map.


Automated visualization of all lesions (>= PI-RADS 3) in a schematic sector map

All lesion details in a tabular view including volume, region, PI-RADS 2.1 score and (optionally) PSA-density

Tabular overview of all relevant lesion metrics and the PI-RADS scores of the current and previous examinations

mdprostate Report with PSA value and longitudinal assessment

Fully-automated prostate segmentation

Our tool automatically calculates the prostate volume, segments the regions according to PI-RADS 2.1 and simplifies your workflow significantly. Optionally, the PSA density can be calculated.

Fully-automated lesion classification (PI-RADS 2.1)

Get a detailed evaluation of classified lesions with clear information about volume, dimensions, ADC values and other parameters.

First AI-tool with longitudinal assessments for the prostate

Experience the first AI-based prostate tool with longitudinal assessments. Easily compare the previous assessment with the current one, integrated into one report (available from version 1.3).

Customise reports quickly and easily for optimal results

While our AI-tool is there to support, you drive the final decision. You have the option to adjust, in case you'll ever need it. Reports only leave the workstation how and when you want to.

With our volume-based tiers, our price adjusts to your needs.
We include a three month money-back guarantee for new customers.



Automated segmentation of zones incl. calculation of volume and PSA density.
Automated assessment of all sequences to detect all lesions.
Diagnosis lays in your hand, our tool helps with intuitive overlays.
Automated localization and measurement of lesions incl. analysis of EPEs as well as further parameters.
Automated determination of PI-RADS score for relevant lesions.
Focus on the evaluation and adapt scoring - if needed - with one click.
Automated drawing for the localization of lesions included in comprehensive reports for referrers.
Forward the ready made report with one click to the referrers.


Zero clicks - speed up your workflow

Automated analysis and report generation with full PACS integration for a lean workflow.

One automated report - no tedious manual steps

All data summarized in one report, generated in less than three minutes, including schematic visualizations.

Two opinions - peace of mind for patients and you

AI lends you a second pair of eyes for detailed and accurate quantitative analysis, for more informed conclusions.

Visual representation of the largest lesions with intuitive overlays

MRI images are evaluated automatically to determine the volume of the prostate and to highlight the three biggest lesions in each of the three image sequences with colored overlays.

The overlays are directly accessible within the PACS to speed up the detection of lesions and integrated into each report with one click. Simplify the communication to referring specialists.

mdprostate MRI evaluation with overlays

Lesion details and PI-RADS scoring with no effort

Without any further effort, you receive a detailed evaluation of the detected lesions including three-dimensional extent, regional assignment and ADC value (min. / mean).

The lesions are ordered according to the PI-RADS classification. After entering the current PSA value in the browser interface, the PSA density is automatically calculated and presented in the report.

mdprostate Tabular Overview of Results

Integrated follow-up monitoring for the rapid assessment of lesion dynamics

The longitudinal assessment allows for a quick comparison of changes in detected lesions to the previous examination. In this way, we provide the first AI tool that offers optimal support for Active Surveillance.

Changes compared to the previous examination are presented in tabular form, and the PI-RADS score is automatically determined. Relevant changes in each individual lesion can thus be easily identified.

Schematic mapping of lesions to avoid tedious drawings

Speed up your report generation with our automated schematic visualizations. No additional tools, no more time-consuming, manual drawings.

The lesion dimensions, the anatomical assignment and the PI-RADS score are illustrated precisely and clearly.

mdprostate Sektorenkarte - Schematische Map 1

Comprehensive perspectives to clearly communicate findings to referring specialists

In the supplemental coronary and sagittal overview, all involved physicians can quickly grasp the lesion extent.

Additionally you have a precise, yet easy-to-understand visualization available when communicating with patients or referring physicians.

mdprostate Sektorenkarte - Schematische Map 2
mdprostate Terminbuchung


We would be happy to advise you on how mdprostate can best support you in your work.

Our md-suite can do even more. Discover our other products.


mdbrain enables AI-powered evaluations of brain MRIs. Currently available modules are Brain Volumetry, Lesion Characterization, Aneurysm Detection, and Tumor Differentiation. As output radiologists receive comprehensive and lucid quantitative reports as well as visual overlays directly into the PACS.


mdbrain and mdprostate are approved as medical devices within the European Union and bear the CE marking. This means that the AI solutions can be used for patients across Europe and are partially reimbursable in accordance with local regulations.

mdbrain and mdprostate can seamlessly work with all DICOM data from standard MRI systems from Siemens, Philips, GE, or Canon/Toshiba with 1.5 or 3T field strength. Even though both solutions can work with a wider range of image qualities, we recommend specifications for optimal results.


Brain volumetry: 3D-T1-MPRAGE sequence with an in-plane resolution of at least 1.0 x 1.0 mm².

Lesion characterization: (3D-)T1 sequence and 3D-T2-FLAIR sequence, both with an in-plane resolution of 1.0 x 1.0 mm².

Aneurysm detection: TOF sequence with an in-plane resolution of 1.0 x 1.0 mm².

Tumor differentiation: 3D-T1 sequence with an in-plane resolution of 1.0 x 1.0 mm², 3D-T2-FLAIR sequence with an in-plane resolution of 1.0 mm x 1.0 mm, T1 sequence with contrast medium with an in-plane resolution of 3.0 x 3.0 mm² and T2-Spin-Echo sequence with an in-plane resolution of 3.0 x 3.0 mm².


  • T2w Spin Echo (SE) with a resolution of at least 0.9 x 0.9 mm², DWI (all) with a resolution of at least 2.5 x 2.5 mm² with a B-value between 1400 and 2000 (measured or calculated), and ADC with a resolution of at least 2.5 x 2.5 mm².
  • We recommend using a 2D T2, as there are no 3D T2 cases included in the training data.


Of course, the existing contrast-enhanced protocol (DCE) can be maintained (provided that the sequence requirements for the above-mentioned sequences are met). However, DCE is not included in the evaluation.

For testing our software, we offer two options: an online demo and an on-premise installation. The online demo is a free, web-based testing opportunity and can be requested by simply registering at this link. For the option of an on-premise test, please contact us at so that our sales and support team can provide you with the individual conditions for testing.

The md-suite, including the software solutions mdbrain and mdprostate, is installed locally in your practice/hospital and can be seamlessly integrated into your PACS. The system requirements are reasonable: A Linux or Ubuntu system with an Intel i7 processor, at least 4 cores, 16GB RAM, and 500GB HDD is sufficient in most cases for smooth analysis. The analysis time can be significantly reduced with the use of a graphics card. We are happy to provide more detailed specifications to your local IT and of course, we are ready to assist with the installation.

The solutions mdbrain and mdprostate are billed according to a Software as a Service (SaaS) model. This means you do not need to purchase the software outright and only pay for as many analyses as you actually use. Additionally, you automatically benefit from future product improvements and expanded functionality. The usage fee depends on the monthly volume of examinations. In addition, we charge a one-time installation fee and a monthly service fee. You achieve the optimal cost-benefit ratio with full automation.

  • Auto-Pull: Automatic check for previously unevaluated studies
  • Auto-Routing: Automatic forwarding of specific studies to the md-suite server
  • Longi-Pull: Automatic inclusion of prior scans for longitudinal evaluation
  • Auto-Send: Automatic integration of all results in your PACS
The analysis and report generation typically takes 3-5 minutes, though this may vary slightly depending on the hardware used. In any case, it's entirely feasible to discuss the results with the patients during the same appointment.
The evaluations of the mdbrain module 'Tumor Differentiation' usually require more time.

The mediaire software solutions mdbrain and mdprostate are part of the md-suite, a closed system integrated within your local IT workflow, ensuring utmost confidentiality. At no point do patient data or reports leave your premises. Therefore, anonymization is not necessary.

The data and reports never leave your practice/hospital, not even in anonymized form. Mediaire's software solutions are specifically designed to ensure the highest level of data protection for patients by keeping all patient information, analysis processes, and reports stored locally in your practice/hospital.


*bald verfügbar 

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH


Experience mdprostate, the first fully-automated AI-tool including longitudinal assessment for the evaluation of prostate MRIs.

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH